Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4216881 | 0.79 | ALDH1A1 (0.70) | KDM4ECACNA1HALDH1A1EPHX1EPHX2 | |
| SCHEMBL4219007 | 0.79 | ALDH1A1 (0.55) | KDM4EALDH1A1EPHX1EPHX2 | |
| SCHEMBL4365559 | 0.77 | ALDH1A1 (0.94) | KDM4ECACNA1HALDH1A1EPHX1 | |
| SCHEMBL15502440 | 0.77 | ALDH1A1 (0.53) | ALDH1A1EPHX1EPHX2 | |
| SCHEMBL26498849 | 0.77 | CACNA1H (1.00) | KDM4ECACNA1HALDH1A1EPHX1 | |
| SCHEMBL4218180 | 0.77 | ALDH1A1 (0.76) | KDM4ECACNA1HALDH1A1 | |
| SCHEMBL4226730 | 0.75 | KDM4E (0.72) | KDM4ECACNA1HALDH1A1EPHX1EPHX2 | |
| SCHEMBL4222713 | 0.75 | ALDH1A1 (0.72) | KDM4ECACNA1HALDH1A1EPHX1EPHX2 | |
| SCHEMBL11439126 | 0.74 | EPHX2 (0.58) | ALDH1A1EPHX2 | |
| SCHEMBL26464310 | 0.74 | CACNA1H (0.92) | KDM4ECACNA1HALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1812407-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | Pfizer, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006048750-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | HSD11B1, HSD11B2, HSD17B11 | KDM4E 2439/4885CACNA1H 2518/4885ALDH1A1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.